Stories

The outputs from the European Society of Medical Oncology (ESMO) Congress this year encompassed several important new data announcements, highlighting key advances in the development of therapies for people living with cancer.  However, cancer remains a formidable global health challenge,…

The European Federation of Pharmaceutical Industries and Associations (EFPIA) has commissioned Dolon to develop a report to assess the impact of the proposed European Commission pharma legislation. The Dolon Report, published on 6 November, has projected that the proposed legislation…

Ipsen plans to host a capital-markets day, starting at 12.30 pm GMT on 7 December 2023, at The Brewery, London. In-person attendance is by invitation only.

Developing innovation for people living with rare diseases is uniquely challenging. It requires all the different pieces of the puzzle– clinical viability, economic viability and the policy environment— to come together before innovation can reach patients.

At Ipsen we have been focused on developing new and innovative treatments for rare diseases for many years in endocrinology, rare bone disease and more recently in rare liver disease. This focus continues to be a core part of our…